Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT06185153

8779

Ages > 18
All Genders

Study Summary

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Adult patient (≥18)
Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022
Subjects who have not expressed their opposition to the reuse of their data forscientific research purposes.

Exclusion

Exclusion Criteria:

Patient having expressed his opposition to the retrospective reuse of his data forscientific research purposes.

Study Design

November 21, 2022

December 31, 2023

Study Description

The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Connect with a study center

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, 67091
France
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.